Tech Company Financing Transactions
IgGenix Funding Round
On 8/5/2020, IgGenix secured $10 million in Series A funding from Khosla Ventures and Parker Price Venture Capital.
Transaction Overview
Company Name
Announced On
8/5/2020
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
Khosla Ventures (Lead Investor)
Proceeds Purpose
The financing will be used to advance the company's novel antibody therapeutics platform for the treatment of food and non-food allergies and other severe allergic conditions.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Blvd. 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
IgGenix is a privately-held biotechnology company taking a revolutionary approach to directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jessica Grossman
Chief Scientific Officer
Richard Boismenu
Chief Technical Officer
Derek Croote
Browse more venture capital transactions:
Prev: 8/5/2020: Indigo Ag venture capital transaction
Next: 8/5/2020: Rippling venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs